TGN: USF technology with potential to transform cancer treatment licensed by TransGenex Nanobiotech

TransGenex Nanobiotech Inc., a research and development company, has announced that its cancer nanotechnology division has exclusively licensed the University of South Florida's "3D tumor cell" technology for all cancer related uses. This marks a first step for the company to evolve technology to product manufacturing. The licensing agreement will enable the company's novel "tumor-on-a-dish" platform and provides TransGenex exclusive rights to commercializing 3D cancer cell culture reagents, as well as provide services such as 3D cell based assay for anti-cancer drug discovery and harnessing its "tumor-on-dish" technology to develop clinical diagnostics for personalized cancer treatment. Continue reading